BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27943017)

  • 1. Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis.
    Wannhoff A; Rupp C; Friedrich K; Knierim J; Flechtenmacher C; Weiss KH; Stremmel W; Gotthardt DN
    Dig Dis Sci; 2017 Feb; 62(2):510-516. PubMed ID: 27943017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Björnsson E; Kilander A; Olsson R
    Liver; 1999 Dec; 19(6):501-8. PubMed ID: 10661684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Hultcrantz R; Olsson R; Danielsson A; Järnerot G; Lööf L; Ryden BO; Wahren B; Broomé U
    J Hepatol; 1999 Apr; 30(4):669-73. PubMed ID: 10207809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
    Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
    Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.
    Ramage JK; Donaghy A; Farrant JM; Iorns R; Williams R
    Gastroenterology; 1995 Mar; 108(3):865-9. PubMed ID: 7875490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
    J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
    Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
    J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis.
    Lindberg B; Arnelo U; Bergquist A; Thörne A; Hjerpe A; Granqvist S; Hansson LO; Tribukait B; Persson B; Broomé U
    Endoscopy; 2002 Nov; 34(11):909-16. PubMed ID: 12430077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience.
    Kuzu UB; Ödemiş B; Suna N; Yıldız H; Parlak E; Dişibeyaz S; Torun S; Akpınar MY; Coşkun O; Turhan N; Yüksel M; Kayaçetin E
    J Gastrointest Cancer; 2016 Mar; 47(1):8-14. PubMed ID: 26537791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Nichols JC; Gores GJ; LaRusso NF; Wiesner RH; Nagorney DM; Ritts RE
    Mayo Clin Proc; 1993 Sep; 68(9):874-9. PubMed ID: 8396700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
    Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Sclerosing Cholangitis: What the Gastroenterologist and Hepatologist Needs to Know.
    Gossard AA; Gores GJ
    Clin Liver Dis; 2017 Nov; 21(4):725-737. PubMed ID: 28987259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis.
    Ahrendt SA; Pitt HA; Nakeeb A; Klein AS; Lillemoe KD; Kalloo AN; Cameron JL
    J Gastrointest Surg; 1999; 3(4):357-67; discussion 367-8. PubMed ID: 10482687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
    Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
    J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Siqueira E; Schoen RE; Silverman W; Martin J; Rabinovitz M; Weissfeld JL; Abu-Elmaagd K; Madariaga JR; Slivka A
    Gastrointest Endosc; 2002 Jul; 56(1):40-7. PubMed ID: 12085033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma.
    Oh HC; Kim MH; Lee KT; Lee JK; Moon SH; Song TJ; Eum J; Park DH; Lee SS; Seo DW; Lee SK
    J Gastroenterol Hepatol; 2010 Dec; 25(12):1831-7. PubMed ID: 21091993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominant strictures in patients with primary sclerosing cholangitis.
    Björnsson E; Lindqvist-Ottosson J; Asztely M; Olsson R
    Am J Gastroenterol; 2004 Mar; 99(3):502-8. PubMed ID: 15056092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Serum Bilirubin Level Correlates With the Development of Cholangiocarcinoma, Subsequent Liver Transplantation, and Death in Patients With Primary Sclerosing Cholangitis.
    Haseeb A; Siddiqui A; Taylor LJ; Cox K; Adler DG
    J Clin Gastroenterol; 2016; 50(5):431-5. PubMed ID: 26927495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristic Features of Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis.
    Ishii Y; Sasaki T; Serikawa M; Kobayashi K; Kamigaki M; Minami T; Okazaki A; Yukutake M; Ishigaki T; Kosaka K; Mouri T; Yoshimi S; Chayama K
    Hepatogastroenterology; 2014 May; 61(131):567-73. PubMed ID: 26176037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation.
    Fisher A; Theise ND; Min A; Mor E; Emre S; Pearl A; Schwartz ME; Miller CM; Sheiner PA
    Liver Transpl Surg; 1995 Mar; 1(2):94-8. PubMed ID: 9346547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.